Business Wire

PUMA

Share
No Time for Waste: PUMA pilots testing for biodegradable RE:SUEDE version of its most iconic sneaker

Sports company PUMA has developed an experimental version of its most iconic sneaker, the SUEDE, to test for a product to make it biodegradable. By doing so, PUMA aims to meet the growing demand for sustainable products for a better future. The RE:SUEDE, which uses the latest technology available today, will be made from more sustainable materials such as Zeology tanned suede, biodegradable TPE and hemp fibres.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005105/en/

The RE:SUEDE experiment is a pilot in circularity, and today’s ultimate expression of the next generation SUEDE – with the ambition to set new standards of sustainability for the iconic shoe. Designed to help address the challenge of waste management in the footwear industry, the RE:SUEDE experiment will allow PUMA to take more responsibility when it comes to tackling the ‘after life’ of its products. The pilot will launch in January 2022, offering 500 selected participants in Germany the chance to join PUMA on its experimental journey towards circularity.

In partnership with PUMA, participants will wear their RE:SUEDEs for six months to test out the durability of a product using biodegradable materials in real life, before sending them back to PUMA via a take back infrastructure, designed to move the products to the next step in the experiment. The sneakers will then be subject to an industrial biodegradation process in a controlled environment at Valor Compostering B.V., owned by Ortessa Groep B.V., a family-run business of waste specialists in the Netherlands. The goal of this step is to determine if Grade A compost can be produced for agricultural use. The findings will help PUMA assess the biodegradable process and unpick essential research and development for the future of sustainable shoe consumption.

The RE:SUEDE experiment is the first circular programme to launch under PUMA’s “Circular Lab” – a new innovation hub, which is led by PUMA’s sustainability and design experts who work to develop the future of the company’s circularity programmes.

This pilot is a recharged, refreshed experiment in circularity, following PUMA’s exploration in the space in 2012, which saw the brand’s first attempt to create a biodegradable sneaker as part of its InCycle collection. Yet after four seasons, the sneaker was discontinued due to low demand and the need for further research and development.

Since 2012, PUMA’s innovation department has worked to address the technological limitations of the InCycle collection in order to apply such learnings into the RE:SUEDE experiment. Improvements include the use of new, innovative materials such as Zeology suede, which is made using a more sustainable tanning process and ensures better comfort for the wearer, when compared to other biodegradable materials evaluated at PUMA. The outsole of the RE:SUEDE has also been improved to ensure optimal wear.

“In 2012, our circular ambition was bold but the technology wasn’t quite there. As they say, with every challenge there’s an opportunity - and we’ve continued to push ourselves to do better by applying our strengths as well as acknowledging and improving on our weaknesses,” said Heiko Desens, PUMA’s Creative Director. “We hope that progress made during the RE:SUEDE experiment: ‘No Time For Waste‘ will help us continue to raise the bar in circularity testing – enabling our consumers to make better fashion choices in the future, so their sneakers can go ‘from Suede to Soil’, without compromising on product style or durability during ownership.”

About the partnership with Ortessa, Desens further comments: “We’re excited to partner with the experts at Ortessa, who share our passion in developing proactive and pragmatic solutions to the industry‘s waste problem. Their expertise is fundamental in helping us learn more about the after life of the RE:SUEDE, so we can continue moving forwards on our exploration of circularity.“

Rob Meulendijks, CEO of Ortessa comments: “As a family owned challenger in the waste industry, we pride ourselves in creating surprising innovations and fresh concepts to tackle real waste issues in a different and open way. There is a lot more we can all be doing to help tackle waste management, but taking on that challenge alone can be a difficult task for any brand. We are delighted to be working in partnership with PUMA on this special project, where we can apply our deep knowledge and insights on waste, use tried and controlled methods, to assess the biodegradability of the future, next-generation Suede.“

PUMA aims to share the results and insights gained from this experiment within the industry to achieve an even bigger impact when it comes to addressing the challenge of waste management in the footwear industry in general. Circularity is one of the pillars of PUMA’s FOREVER BETTER sustainability strategy. By 2025, PUMA aims to reduce waste by increasing the level of recycled polyester in its products to 75%, setting up product takeback schemes in its major markets and developing recycled material options for leather, rubber, cotton and polyurethane.

Since its first iteration in 1968, the PUMA SUEDE has been at the forefront of cultural turning points, transcending style and trends. With the RE:SUEDE, PUMA wants to give its consumers a stylish and more sustainable choice, while showcasing the latest technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye